anti-Prostate Specific Antigen, Total antibody product blog
Tags: Antibody; Monoclonal Antibody; Prostate Specific Antigen, Total; anti-Prostate Specific Antigen, Total antibody;
The Prostate Specific Antigen, Total n/a (Catalog #MBS631939) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Prostate Specific Antigen, Total (Total PSA) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Prostate Specific Antigen, Total can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA).Suitable for use in ELISA. Researchers should empirically determine the suitability of the Prostate Specific Antigen, Total n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
PSA is a chymotrypsin-like serine protease (kallikrein family) produced by the prostate epithelium, and abundant in seminal fluid. PSA can be detected in the sera of patients with prostatic carcinoma. It is predominantly complexed to a liver-derived serine protease inhibitor, alpha-1-antichymotrypsin (ACT). A higher proportion of serum PSA is complexed to ACT in prostate cancer than in benign prostate hyperplasia. Anti-PSA is useful in the positive identification of metastatic deposits of prostatic origin.
Immunogen: Human PSA antigen purified from seminal plasma. Hybridoma: Sp2/0 myeloma cells with spleen cells from Balb/c mice. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Prostate Specific Antigen, Total are readily searchable from our website. Different antibodies against the same target such as Prostate Specific Antigen, Total may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.